TP53 and amyloidosis: Indeed, a variety of amyloid inhibitor CPP constructs have been developed that have yielded potent therapeutic effects across a wide range of amyloid diseases, from inhibition of Aβ self-assembly and the associated cytotoxicity in neuronal cell lines, to dissociation of mutant p53 amyloid-like aggregates in inactive cytosolic inclusions in cancer cell lines, which restores the protein’s transcriptional activity, leading to cell cycle arrest and apoptosis [150,164].